We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Molecular Pathway Leads to Pancreatic Cancer

By LabMedica International staff writers
Posted on 25 Feb 2013
Cancer researchers have outlined the molecular pathway that regulates the transformation of normal pancreatic tissue into pancreatic ductal adenocarcinoma cells.

Investigators at the University of Pennsylvania (Philadelphia, USA) profiled gene expression in mouse pancreatic tissues from several different biological states: during embryonic development, acute pancreatitis, and K-ras mutation-driven carcinogenesis. More...
Of particular interest were changes that occurred in exocrine cells during acinar-ductal metaplasia (ADM), an inflammatory state that is a prelude to the development of pancreatic ductal adenocarcinoma.

They reported in the February 2013 issue of the journal Genes and Development that the protein Prrx1 (paired related homeobox 1) was a key element in the pathway leading to transformation into cancer. Prxx1 is a DNA-associated protein that is a member of the paired family of homeobox proteins localized to the nucleus. The protein functions as a transcription coactivator, enhancing the DNA-binding activity of serum response factor, a protein required for the induction of genes by growth and differentiation factors.

Results of the current study revealed that Prxx1was present in two isoforms, Prrx1a and Prrx1b. Prxx1a was shown to regulate migration while Prxx1b regulated invasion in pancreatic cancer cells and was enriched in circulating pancreatic cells. Additionally, the Prrx1b isoform, which was also induced in ADM, bound the Sox9 promoter and positively regulated Sox9 expression. This finding suggested a new hierarchical scheme whereby a Prrx1–Sox9 axis may influence the emergence of ADM and regeneration.

“We hope that studies like this one that identifies key molecules and pathways that govern the cancerous fate of cells can be used as diagnostic predictors of treatment outcome and severity for cancer,” said senior author Dr. Anil Rustgi, professor of gastroenterology at the University of Pennsylvania.

Related Links:
University of Pennsylvania


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.